发布时间:
2026
-
05
-
09
BEIJING, CHINA, May 8, 2026 – Beijing Biostar Pharmaceuticals Co., Ltd. (2563.HK, "Biostar Pharma"), a biopharmaceutical company leveraging its synthetic biology R&D platform to develop innovative anticancer drugs with proprietary intellectual property, today announced that Baheal Pharmaceutical (301015.SZ) has subscribed to 25 million new shares issued by Biostar Pharma. Upon completion of the issuance, Biostar Pharma will receive HK$100 million in subscription proceeds, and Baheal Pharmaceutical will hold an aggregate of 29,170,800 shares, representing 7.49% of the Co...
浏览次数:3